STOCK TITAN

LAVA Therapeutics NV - LVTX STOCK NEWS

Welcome to our dedicated news page for LAVA Therapeutics NV (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on LAVA Therapeutics NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LAVA Therapeutics NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LAVA Therapeutics NV's position in the market.

Rhea-AI Summary
LAVA Therapeutics N.V. has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., to evaluate its anti-PD-1 therapy KEYTRUDA® in combination with LAVA-1207, a Gammabody® designed to target PSMA, in patients with therapy refractory mCRPC. Enrollment will continue in the monotherapy and IL-2 combination arms of the study, with the combination arm expected to be initiated in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.95%
Tags
none
-
Rhea-AI Summary
LAVA Therapeutics N.V. (Nasdaq: LVTX) announced recent corporate highlights and financial results for the quarter ended September 30, 2023. The company continues to advance its lead program, LAVA-1207, in patients with mCRPC in a Phase 1/2a escalation study. They also initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) in advanced solid tumors. The company's strong balance sheet with cash runway into 2026 positions LAVA well to bring benefits to patients and deliver shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
earnings
-
Rhea-AI Summary
LAVA Therapeutics CEO to participate in virtual fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
conferences
Rhea-AI Summary
LAVA Therapeutics announces progress with lead program LAVA-1207 and partnered programs, portfolio reprioritization, and extension of cash runway into 2026. Cash, cash equivalents, and investments as of June 30, 2023, were $112.4 million. Revenue from contracts with customers was $5.1 million for Q2 2023. Loss for the period was $12.7 million. LAVA-1223 IND clearance received. Staff reduction and cost savings associated with discontinuation of LAVA-051. Loss per share was $0.48 for Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.66%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.07%
Tags
earnings
-
Rhea-AI Summary
LAVA Therapeutics announces that Janssen has chosen a lead candidate for further development in the treatment of cancer through their research collaboration. Janssen will be responsible for clinical development, manufacture, and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.84%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
none
LAVA Therapeutics NV

Nasdaq:LVTX

LVTX Rankings

LVTX Stock Data

57.84M
10.22M
28.58%
40.25%
0.04%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Utrecht